ELREXFIO Results
ELREXFIO was studied in a clinical trial that included people with relapsed or refractory multiple myeloma. This trial included 2 groups:
This group included 97 people who had never previously tried a BCMA-directed therapy. Their cancer came back or did not respond to at least 4 treatment regimens, including:
- A proteasome inhibitor
- An immunomodulatory agent
- An anti-CD38 monoclonal antibody
Group A Results
- In Group A, 58% of people responded to ELREXFIO
- This is the overall response rate (ORR) and includes anyone who had at least a partial response to treatment.
- In Group A, results with ELREXFIO showed:
- 26% of people had a CR or better: Multiple myeloma could not be detected in the blood or urine after treatment.
- 26% of people had a VGPR: A decrease of at least 90% in M-protein levels.
- 6% of people had a PR: A decrease of at least 50% in M-protein levels.
Half of those who responded to ELREXFIO began seeing results within 37 days
In a clinical trial, some people responded to ELREXFIO in less than 1 month, while others responded in a little over 6 months. The median, or amount of time where half responded sooner and half responded later, was 37 days.
- 82% of responding patients were predicted to still be responding at 9 MONTHS
- This is also known as the duration of response, which means that of those people who responded to ELREXFIO, the likelihood of them still responding to treatment at 9 months was 82%. These responses are ongoing and may change in the future as researchers continue to look at results from the trial.
This group included 63 people who had previously tried a BCMA-directed therapy. Their cancer came back or did not respond to at least 4 treatment regimens, including:
- A proteasome inhibitor
- An immunomodulatory agent
- An anti-CD38 monoclonal antibody
These people had previously taken a BCMA-directed antibody drug conjugate (ADC) treatment and/or a chimeric antigen receptor T cell (CAR T cell) treatment.
Group B Results
This group included 63 people who had tried at least 4 treatment regimens and who had tried a BCMA-directed therapy.
- In Group B, 33% of people responded to ELREXFIO
- This overall response rate (ORR) included anyone who experienced at least a partial response to treatment.
